08:48 AM EDT, 05/30/2025 (MT Newswires) -- Pfizer ( PFE ) said Friday that braftovi in combination with cetuximab and mFOLFOX6 cut the risk of death by 51% compared with standard-of-care chemotherapy with or without bevacizumab in a phase 3 metastatic colorectal cancer trial.

The overall survival rate is a key secondary endpoint of the study, according to Pfizer ( PFE ).

The combination regimen also lowered the risk of disease progression or death by 47%, achieving the study's dual primary endpoint of progression-free survival, the company said.

Pfizer ( PFE ) said the regimen received the US Food and Drug Administration's accelerated approval in December 2024 for patients with BRAF V600-mutant metastatic colorectal cancer due to an improvement in the confirmed objective response rate in treatment-naive patients, the trial's other dual primary endpoint.